Display options
Cite
Porter RJ, Murray GI, Alnabulsi A, et al. Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8. J Pathol Clin Res. 2021;7(5):495-506doi: 10.1002/cjp2.222.
Porter, R. J., Murray, G. I., Alnabulsi, A., Humphries, M. P., James, J. A., Salto-Tellez, M., Craig, S. G., Wang, J. M., Yoshimura, T., & McLean, M. H. (2021). Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8. The journal of pathology. Clinical research, 7(5), 495-506. https://doi.org/10.1002/cjp2.222
Porter, Ross J, et al. "Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8." The journal of pathology. Clinical research vol. 7,5 (2021): 495-506. doi: https://doi.org/10.1002/cjp2.222
Porter RJ, Murray GI, Alnabulsi A, Humphries MP, James JA, Salto-Tellez M, Craig SG, Wang JM, Yoshimura T, McLean MH. Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8. J Pathol Clin Res. 2021 Sep;7(5):495-506. doi: 10.1002/cjp2.222. Epub 2021 May 14. PMID: 33988317; PMCID: PMC8363930.
Copy Download .nbib Format: NLM
Share it on

J Pathol Clin Res. 2021 Sep;7(5):495-506. doi: 10.1002/cjp2.222. Epub 2021 May 14.

Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8.

The journal of pathology. Clinical research

Ross J Porter, Graeme I Murray, Abdo Alnabulsi, Matthew P Humphries, Jacqueline A James, Manuel Salto-Tellez, Stephanie G Craig, Ji M Wang, Teizo Yoshimura, Mairi H McLean

Affiliations

  1. Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK.
  2. School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
  3. Precision Medicine Centre of Excellence, The Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
  4. Integrated Pathology Programme, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  5. Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA.
  6. Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  7. Division of Molecular & Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK.

PMID: 33988317 PMCID: PMC8363930 DOI: 10.1002/cjp2.222

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer mortality. Here, we define the colonic epithelial expression of cathelicidin (LL-37) in CRC. Cathelicidin exerts pleotropic effects including anti-microbial and immunoregulatory functions. Genetic knockout of cathelicidin led to increased size and number of colorectal tumours in the azoxymethane-induced murine model of CRC. We aimed to translate this to human disease. The expression of LL-37 in a large (n = 650) fully characterised cohort of treatment-naïve primary human colorectal tumours and 50 matched normal mucosa samples with associated clinical and pathological data (patient age, gender, tumour site, tumour stage [UICC], presence or absence of extra-mural vascular invasion, tumour differentiation, mismatch repair protein status, and survival to 18 years) was assessed by immunohistochemistry. The biological consequences of LL-37 expression on the epithelial barrier and immune cell phenotype were assessed using targeted quantitative PCR gene expression of epithelial permeability (CLDN2, CLDN4, OCLN, CDH1, and TJP1) and cytokine (IL-1β, IL-18, IL-33, IL-10, IL-22, and IL-27) genes in a human colon organoid model, and CD3

© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.

Keywords: LL-37; cathelicidin; colorectal cancer; lymphocytes; organoid

References

  1. J Cell Sci. 2017 Jan 15;130(2):307-314 - PubMed
  2. Nat Commun. 2014 Dec 03;5:5621 - PubMed
  3. Crit Rev Immunol. 2019;39(2):83-92 - PubMed
  4. Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704 - PubMed
  5. Br J Cancer. 2020 Feb;122(4):545-554 - PubMed
  6. Adv Exp Med Biol. 2019;1117:149-171 - PubMed
  7. J Immunol. 2018 Mar 15;200(6):2174-2185 - PubMed
  8. Oncoimmunology. 2019 May 1;8(8):1608106 - PubMed
  9. Oncotarget. 2016 Jul 19;7(29):46509-46527 - PubMed
  10. Cancer Microenviron. 2013 Aug;6(2):123-33 - PubMed
  11. J Immunol. 2017 Feb 15;198(4):1696-1705 - PubMed
  12. Cancer Treat Rev. 2020 Feb;83:101949 - PubMed
  13. Respir Res. 2019 Nov 9;20(1):251 - PubMed
  14. N Engl J Med. 2013 Jan 17;368(3):282-4 - PubMed
  15. Br J Cancer. 2017 Jun 6;116(12):1612-1620 - PubMed
  16. Arch Immunol Ther Exp (Warsz). 2016 Feb;64(1):33-46 - PubMed
  17. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  18. Int J Cancer. 2019 Aug 15;145(4):1138-1147 - PubMed
  19. Lancet. 2018 May 26;391(10135):2128-2139 - PubMed
  20. Br J Cancer. 2020 Oct;123(8):1209-1218 - PubMed
  21. Science. 2006 Sep 29;313(5795):1960-4 - PubMed
  22. Genome Res. 2012 Feb;22(2):299-306 - PubMed
  23. Cell Physiol Biochem. 2018;47(3):1060-1073 - PubMed
  24. Gastroenterology. 2011 Nov;141(5):1762-72 - PubMed
  25. Ann Surg Oncol. 2020 Oct;27(10):3997-4006 - PubMed
  26. Clin Exp Gastroenterol. 2014 Dec 17;8:13-29 - PubMed
  27. Sci Rep. 2017 Dec 4;7(1):16878 - PubMed
  28. Int J Cancer. 2018 Feb 15;142(4):822-832 - PubMed
  29. Nat Rev Microbiol. 2012 Jun 25;10(8):575-82 - PubMed
  30. PLoS One. 2012;7(10):e46476 - PubMed
  31. Methods. 2001 Dec;25(4):402-8 - PubMed
  32. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  33. Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):539-548 - PubMed
  34. Cancer Res. 2012 Dec 15;72(24):6512-23 - PubMed
  35. Br J Cancer. 2020 Oct;123(8):1280-1288 - PubMed
  36. Sci Rep. 2020 Feb 25;10(1):3360 - PubMed
  37. Cancer Genet. 2018 Jan;220:49-76 - PubMed
  38. Genome Res. 2012 Feb;22(2):292-8 - PubMed
  39. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed

Publication Types

Grant support